Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]3-iodoallyl-2-(3-iodobenzyl)guanidine
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]3-iodoallyl-2-(3-iodobenzyl)guanidine (also referred to as [11C]mIBG-iodopropene) is a carbon-11 radiolabeled asymmetric guanidine analog of meta-iodobenzylguanidine (mIBG) developed by researchers at the University of Michigan. It is designed as a positron emission tomography (PET) imaging tracer to target the norepinephrine transporter (NET) and vesicular monoamine transporter 2 (VMAT2) for the diagnosis and evaluation of neuroendocrine tumors, such as neuroblastoma, pheochromocytoma, and paraganglioma. By incorporating a carbon-11 radiolabel on the guanidine moiety and an iodine-bearing allyl side chain, this tracer serves as a preclinical prototype to evaluate the uptake and retention kinetics of novel mIBG analogs, which may subsequently be labeled with therapeutic radionuclides like iodine-131 or astatine-211 for theranostic applications.
- Other names
- [11C]mIBG-iodopropene[11C]mIBG-iodopropene-3-iodoallyl-2-(3-iodobenzyl)guanidine3-iodoallyl-2-(3-iodobenzyl)guanidinemIBG-iodopropene
02
Targets
NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on [11C]3-iodoallyl-2-(3-iodobenzyl)guanidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]3-iodoallyl-2-(3-iodobenzyl)guanidine.